SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Tissue-targeted nucleic acid delivery

Getting mRNA, DNA or editor payloads into a chosen tissue outside the liver at therapeutic dose, with redosing possible. (CNS delivery is covered separately.)

State of the art

Polymer-lipid nanoparticles delivering Dsup mRNA produced protective protein expression confined to mouse oral and rectal tissue (Nature Biomedical Engineering, 2025); approved LNP and AAV products target liver, eye and muscle only.

What’s blocking it
  • Systemic LNPs partition to liver and spleen; tropism for kidney, bone marrow and solid tumors is weak
  • Anti-AAV immunity excludes many patients and blocks redosing
  • Payload size caps (about 4.7 kb for AAV) exclude large multi-gene constructs

Who’s working on it

  • Daniel SiegwartResearcher
    UT Southwestern Medical Center

    Invented selective organ targeting lipid nanoparticles that redirect mRNA to lung and spleen, and in 2025 traced the effect to protein-corona composition

  • Dyno TherapeuticsStartup

    Designs AAV capsids with machine learning; licensed a CNS capsid to Roche in January 2025 and had a skeletal-muscle capsid optioned by Astellas

  • Capsida BiotherapeuticsStartup

    Engineers tissue-selective capsids paired with its own manufacturing, aimed specifically at targets outside the liver

  • Tessera TherapeuticsStartup

    Its proprietary lipid nanoparticles delivered Gene Writers to haematopoietic stem cells and T cells in primates with editing durable to about 15 months (2025)

  • Giovanni TraversoResearcher
    Massachusetts Institute of Technology

    Produced tissue-confined mRNA expression in mouse oral and rectal mucosa using polymer-lipid nanoparticles (Nature Biomedical Engineering, 2025)

  • Alnylam PharmaceuticalsCompany

    Its approved GalNAc-conjugated siRNA drugs define what reliable delivery looks like and also define the ceiling, since they reach only hepatocytes

What to invest in

KindInvestmentScale
researchDirected-evolution and designed-capsid campaigns validated in nonhuman primates for three non-liver target tissues$$$ $100M – $1B
engineeringManufacturing and release-assay capacity for clinical-grade vectors at 1e16 genome doses$$$ $100M – $1B

Sci-fi concepts in reach

Engineered human adaptation to other worldsindirectWhole-body rejuvenation treatmentdirectEngineered pandemic organismdirect

Sources